908 Devices Beheer
Beheer criteriumcontroles 4/4
De CEO 908 Devices is Kevin Knopp, benoemd in Feb2012, heeft een ambtstermijn van 14.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.55M, bestaande uit 32.2% salaris en 67.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.54% van de aandelen van het bedrijf, ter waarde $ 11.06M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.4 jaar en 5.3 jaar.
Belangrijke informatie
Kevin Knopp
Algemeen directeur
US$1.6m
Totale compensatie
| Percentage CEO-salaris | 32.19% |
| Dienstverband CEO | 14.3yrs |
| Eigendom CEO | 3.5% |
| Management gemiddelde ambtstermijn | 3.4yrs |
| Gemiddelde ambtstermijn bestuur | 5.3yrs |
Recente managementupdates
Recent updates
MASS: Raised 2026 Revenue Outlook Will Support Higher Future P/E Multiple
Analysts have modestly adjusted their price targets on 908 Devices, reflecting updated assumptions for a fair value of $10.00, a slightly higher discount rate, marginally stronger projected revenue growth, a softer profit margin outlook, and a higher future P/E of about 70x. What's in the News 908 Devices raised its full year 2026 revenue guidance to a range of $67.0 million to $70.0 million.908 Devices Looking Better Now (Rating Upgrade)
Summary 908 Devices delivered strong Q1 results, raising full-year revenue guidance after a strategic acquisition in narcotics detection. Adjusted gross margins improved nearly three percentage points to 57%, and operating cash flow turned positive. MASS has a solid balance sheet with nearly $100 million in cash post-acquisition and is debt free, while trading at a reasonable valuation. Read the full article on Seeking AlphaMASS: Raised 2026 Revenue Guidance Will Support Higher Earnings Multiple
Analysts have reset their price target on 908 Devices to $10.00 from $8.00, citing updated assumptions around revenue growth, profitability, and future P/E that feed into a higher fair value estimate and a modestly higher discount rate. What's in the News 908 Devices raised full year 2026 revenue guidance to a range of $67.0 million to $70.0 million, compared with 2025 revenue, with the range described as representing 19% to 25% growth (Corporate Guidance: Raised).908 Devices Inc.'s (NASDAQ:MASS) 29% Price Boost Is Out Of Tune With Revenues
Those holding 908 Devices Inc. ( NASDAQ:MASS ) shares would be relieved that the share price has rebounded 29% in the...Some 908 Devices Inc. (NASDAQ:MASS) Shareholders Look For Exit As Shares Take 26% Pounding
908 Devices Inc. ( NASDAQ:MASS ) shareholders won't be pleased to see that the share price has had a very rough month...908 Devices Inc.'s (NASDAQ:MASS) Share Price Not Quite Adding Up
When close to half the companies in the Electronic industry in the United States have price-to-sales ratios (or "P/S...908 Devices Inc. (NASDAQ:MASS) Analysts Are Pretty Bullish On The Stock After Recent Results
NasdaqGM:MASS 1 Year Share Price vs Fair Value Explore 908 Devices's Fair Values from the Community and select yours...
US Federal And International Funding Will Expand Global Analysis Markets
The notable increase in 908 Devices’ price target reflects improved outlook due to higher expected revenue growth and an expanded forward P/E, raising the consensus fair value from $6.50 to $9.00. What's in the News 908 Devices raised its 2025 revenue guidance to $54–56 million (13–17% growth), up from prior guidance of $53–55 million.908 Devices Inc.'s (NASDAQ:MASS) Shares Climb 26% But Its Business Is Yet to Catch Up
Despite an already strong run, 908 Devices Inc. ( NASDAQ:MASS ) shares have been powering on, with a gain of 26% in the...
The New Handheld Mass Spectrometer Launch Will Expand Market Reach
Divesting the desktop bioprocessing portfolio boosts cash reserves, streamlines operations, and is expected to enhance margins and cash flow in future years.908 Devices Makes Key Divestiture (Rating Upgrade)
Summary 908 Devices' stock surged after announcing a $70 million desktop portfolio sale, doubling its cash position and improving financial stability. The company will now focus on its handheld device business, expecting 11% to 15% revenue growth in 2025 with acceleration in 2026. MASS management believes losses will be significantly reduced with the new structure, with positive cash flow next year. Read the full article on Seeking Alpha908 Devices Inc.'s (NASDAQ:MASS) 55% Jump Shows Its Popularity With Investors
The 908 Devices Inc. ( NASDAQ:MASS ) share price has done very well over the last month, posting an excellent gain of...Earnings Update: 908 Devices Inc. (NASDAQ:MASS) Just Reported And Analysts Are Trimming Their Forecasts
The analysts might have been a bit too bullish on 908 Devices Inc. ( NASDAQ:MASS ), given that the company fell short...908 Devices: Key Investor Now Selling
Summary ARK Invest's recent sales of 908 Devices shares have helped to send the stock to multi-year lows. 908 Devices is seeing decent revenue growth, but large losses and limited financial flexibility raise concerns about future capital needs. The stock's low valuation compared to peers is a positive, but ongoing sales by ARK Invest could exert further downward pressure. Read the full article on Seeking AlphaWhy We're Not Concerned Yet About 908 Devices Inc.'s (NASDAQ:MASS) 29% Share Price Plunge
To the annoyance of some shareholders, 908 Devices Inc. ( NASDAQ:MASS ) shares are down a considerable 29% in the last...We Think 908 Devices (NASDAQ:MASS) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Investors Appear Satisfied With 908 Devices Inc.'s (NASDAQ:MASS) Prospects
When you see that almost half of the companies in the Electronic industry in the United States have price-to-sales...908 Devices Q2 2022 Earnings Preview
908 Devices (NASDAQ:MASS) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.26 (+3.7% Y/Y) and the consensus Revenue Estimate is $10.79M (+30.5% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 2 downward. Revenue estimates have seen 0 upward revisions and 2 downward.Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$35m |
| Dec 31 2025 | US$2m | US$500k | -US$33m |
| Sep 30 2025 | n/a | n/a | -US$73m |
| Jun 30 2025 | n/a | n/a | -US$81m |
| Mar 31 2025 | n/a | n/a | -US$57m |
| Dec 31 2024 | US$2m | US$498k | -US$53m |
| Sep 30 2024 | n/a | n/a | -US$45m |
| Jun 30 2024 | n/a | n/a | -US$28m |
| Mar 31 2024 | n/a | n/a | -US$30m |
| Dec 31 2023 | US$1m | US$475k | -US$36m |
| Sep 30 2023 | n/a | n/a | -US$39m |
| Jun 30 2023 | n/a | n/a | -US$38m |
| Mar 31 2023 | n/a | n/a | -US$37m |
| Dec 31 2022 | US$2m | US$477k | -US$34m |
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$26m |
| Mar 31 2022 | n/a | n/a | -US$25m |
| Dec 31 2021 | US$760k | US$400k | -US$22m |
| Sep 30 2021 | n/a | n/a | -US$29m |
| Jun 30 2021 | n/a | n/a | -US$26m |
| Mar 31 2021 | n/a | n/a | -US$18m |
| Dec 31 2020 | US$591k | US$284k | -US$13m |
| Sep 30 2020 | n/a | n/a | -US$3m |
| Jun 30 2020 | n/a | n/a | -US$6m |
| Mar 31 2020 | n/a | n/a | -US$11m |
| Dec 31 2019 | US$445k | US$287k | -US$13m |
Compensatie versus markt: De totale vergoeding ($USD 1.55M ) Kevin } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.51M ).
Compensatie versus inkomsten: De vergoeding van Kevin is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Kevin Knopp (53 yo)
Dr. Kevin J. Knopp, Ph D., Co-Founded 908 Devices Inc. in 2012 and serves as its Chief Executive Officer, President and Director since February 2012. Dr. Knopp Co-Founded Ahura Scientific, Inc. in 2002 and...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 14.3yrs | US$1.55m | 3.54% $ 11.1m | |
| Co-Founder | 14.4yrs | geen gegevens | 2.32% $ 7.2m | |
| CFO & Treasurer | 12.3yrs | US$1.14m | 0.35% $ 1.1m | |
| Chief Legal | less than a year | US$1.33m | geen gegevens | |
| Vice President of Corporate Marketing and Communications | 2.3yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Sales and Product Marketing | no data | US$1.03m | 0.15% $ 477.9k | |
| Vice President of Human Resources | 4.4yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Products and Production | less than a year | geen gegevens | 0.12% $ 371.5k | |
| Chief Business & Strategy Officer | less than a year | geen gegevens | geen gegevens |
Ervaren management: Het managementteam van MASS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 14.3yrs | US$1.55m | 3.54% $ 11.1m | |
| Co-Founder | 1.3yrs | geen gegevens | 2.32% $ 7.2m | |
| Independent Director | 14yrs | US$202.51k | 0.067% $ 209.1k | |
| Independent Director | 5.3yrs | US$200.43k | 0.071% $ 221.7k | |
| Independent Chairman of the Board | 12.8yrs | US$222.51k | 1.27% $ 4.0m | |
| Independent Director | 14yrs | US$200.01k | 0.20% $ 622.4k | |
| Independent Director | 4.3yrs | US$183.34k | 0.080% $ 248.8k | |
| Independent Director | 2yrs | US$175.01k | 0.017% $ 53.6k | |
| Independent Director | less than a year | US$216.63k | 0% $ 0 |
Ervaren bestuur: De raad van bestuur van MASS wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/14 03:05 |
| Aandelenkoers aan het einde van de dag | 2026/06/12 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
908 Devices Inc. wordt gevolgd door 4 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Puneet Souda | Leerink Partners LLC |
| Daniel Arias | Stifel, Equities Research |
| Brendan Smith | TD Cowen |